【中文】2024 年 9 月 6 日获美国 FDA 批准信并实现美国获批上市。FDA 批准适应症：用于无法口服给药时的高血压短期治疗。
【English】Received the FDA approval letter on September 6, 2024, and was approved for marketing in the U.S. FDA-approved indication: short-term treatment of hypertension when oral therapy is not feasible.
